Entia Biosciences, Inc announced a private placement of series A convertible preferred stock for gross proceeds of $1,500,000 on November 13, 2013. The transaction was led by members of the company's board of directors and investment banker, who collectively purchased more than 25% of the total preferred stock. The transaction included participation from new investors.